Inventor · disambiguated record
Tasuku Honjo
Also filed as: HONJO TASUKU
40 granted patents·17 pending applications·2,869 citations·filing 1986–2022
98Inventor score
Files withONO PHARMACEUTICAL CO26UNIV KYOTO10HONJO TASUKU7FOUNDATION FOR BIOMEDICAL RES AND INNOVATION AT KOBE2JAPAN TOBACCO INC2
Top patents by PatentIndex Score
57 records- 0198US9439962B2Immunopotentiative compositionONO PHARMACEUTICAL CO·Filed 2016·Granted Sep 13, 2016·67 cites·30 claims
- 0298US9402899B2Immunopotentiative compositionONO PHARMACEUTICAL CO·Filed 2014·Granted Aug 2, 2016·93 cites·67 claims
- 0398US9393301B2Immunopotentiative compositionONO PHARMACEUTICAL CO·Filed 2016·Granted Jul 19, 2016·76 cites·30 claims
- 0498US9073994B2Immunopotentiative compositionONO PHARMACEUTICAL CO·Filed 2014·Granted Jul 7, 2015·217 cites·30 claims
- 0598US9067999B1Immunopotentiative compositionONO PHARMACEUTICAL CO·Filed 2015·Granted Jun 30, 2015·173 cites·30 claims
- 0698US8728474B2Immunopotentiative compositionHONJO TASUKU·Filed 2010·Granted May 20, 2014·305 cites·17 claims
- 0798US8168179B2Treatment method using anti-PD-L1 antibodyHONJO TASUKU·Filed 2009·Granted May 1, 2012·349 cites·8 claims
- 0898US7595048B2Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1ONO PHARMACEUTICAL CO·Filed 2003·Granted Sep 29, 2009·473 cites·4 claims
- 0998US7563869B2Substance specific to human PD-1ONO PHARMACEUTICAL CO·Filed 2004·Granted Jul 21, 2009·204 cites·4 claims
- 1097US7858746B2Substance that specifically recognizes PD-1ONO PHARMACEUTICAL CO·Filed 2008·Granted Dec 28, 2010·60 cites·2 claims
- 1196US8246955B2Substance specific to human PD-1HONJO TASUKU·Filed 2011·Granted Aug 21, 2012·54 cites·5 claims
- 1296US7998479B2Substance specific to human PD-1ONO PHARMACEUTICAL CO·Filed 2009·Granted Aug 16, 2011·57 cites·2 claims
- 1395US5698520APeptide related to human programmed cell death and DNA encoding the sameONO PHARMACEUTICAL CO·Filed 1996·Granted Dec 16, 1997·184 cites·4 claims
- 1494US7414171B2PD-1-lacking mouse and use thereofONO PHARMACEUTICAL CO·Filed 2001·Granted Aug 19, 2008·44 cites·3 claims
- 1594US5629204APeptide related to human programmed cell death and DNA encoding itONO PHARMACEUTICAL CO·Filed 1995·Granted May 13, 1997·127 cites·4 claims
- 1692US8951518B2Substance specific to human PD-1HONJO TASUKU·Filed 2012·Granted Feb 10, 2015·16 cites·4 claims
- 1791US6815194B2Cytidine deaminaseTAKEDA CHEMICAL INDUSTRIES LTD·Filed 2001·Granted Nov 9, 2004·29 cites·59 claims
- 1889US9783609B2Substance specific to human PD-1ONO PHARMACEUTICAL CO·Filed 2014·Granted Oct 10, 2017·8 cites·8 claims
- 1988US7314621B2Cytidine deaminaseUNIV KYOTO·Filed 2006·Granted Jan 1, 2008·9 cites·18 claims
- 2088US5563048AHuman stromal derived factor 1α and 1β, and DNAs encoding the sameONO PHARMACEUTICAL CO·Filed 1994·Granted Oct 8, 1996·66 cites·12 claims
- 2186US5525486AProcess for constructing cDNA library, and novel polypeptide and DNA coding for the sameTASUKU HONJO·Filed 1994·Granted Jun 11, 1996·80 cites·3 claims
- 2285US7083966B2Cytidine deaminaseUNIV KYOTO·Filed 2004·Granted Aug 1, 2006·11 cites·7 claims
- 2385US5756084AHuman stromal derived factor 1α and 1βONO PHARMACEUTICAL CO·Filed 1996·Granted May 26, 1998·60 cites·8 claims
- 2483US7998491B2Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptideONO PHARMACEUTICAL CO·Filed 2010·Granted Aug 16, 2011·2 cites·2 claims
- 2580US7794975B2Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptideONO PHARMACEUTICAL CO·Filed 2007·Granted Sep 14, 2010·2 cites·5 claims
- 2675US7217786B2Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptideONO PHARMACEUTICAL CO·Filed 2005·Granted May 15, 2007·3 cites·4 claims
- 2775US6096878AHuman immunoglobulin VH gene segments and DNA fragments containing the sameJAPAN TOBACCO INC·Filed 1993·Granted Aug 1, 2000·38 cites·8 claims
- 2875US4816565AInterleukin 2 receptor and a method for production thereofTASUKU HONJO·Filed 1986·Granted Mar 28, 1989·28 cites·2 claims
- 2973US7407767B2Method of screening remedy for heart disease and medicinal composition for treating heart diseaseONO PHARMACEUTICAL CO·Filed 2004·Granted Aug 5, 2008·10 cites·2 claims
- 3072US6936705B1Human immunoglobulin VH gene segments and DNA fragments containing the sameJAPAN TOBACCO INC·Filed 2000·Granted Aug 30, 2005·4 cites·14 claims
- 3171US2020062846A1Immunopotentiative compositionHONJO TASUKU·Filed 2019·Application pending·0 cites
- 3268US11662339B1Efficacy determination markers in disease treatment by PD-1 signal inhibitorUNIV KYOTO·Filed 2017·Granted May 30, 2023·1 cites·18 claims
- 3366US6900031B2Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptideONO PHARMACEUTICAL CO·Filed 2002·Granted May 31, 2005·4 cites·7 claims
- 3463US7749758B2Human and mammalian stem cell-derived neuron survival factorsONO PHARMACEUTICAL CO·Filed 2007·Granted Jul 6, 2010·0 cites·4 claims
- 3563US2017051060A1Immunopotentiative CompositionHONJO TASUKU·Filed 2016·Application pending·0 cites
- 3663US2023272077A1Pd-1 signal inhibitor combination therapyUNIV KYOTO·Filed 2022·Application pending·0 cites
- 3763US2023265193A1Pd-1 signal inhibitor combination therapyUNIV KYOTO·Filed 2022·Application pending·0 cites
- 3861US7255998B1High sensitivity immunoassay methodJAPAN SCIENCE & TECH CORP·Filed 2000·Granted Aug 14, 2007·6 cites·14 claims
- 3961US2005003488A1Polypeptide, cDNA encoding the same, and use of themONO PHARMACEUTICAL CO·Filed 2004·Application pending·0 cites
- 4058US7662620B2Human and mammalian stem cell-derived neuron survival factorsONO PHARMACEUTICAL CO·Filed 2004·Granted Feb 16, 2010·0 cites·4 claims
- 4155US2002086364A1Polypeptide, cDNA encoding the same, and use of themONO PHARMACEUTICAL CO·Filed 2001·Application pending·0 cites
- 4254US7273725B2Human and mammalian stem cell-derived neuron survival factorsONO PHARMACEUTICAL CO·Filed 2002·Granted Sep 25, 2007·0 cites·3 claims
- 4354US2002165151A1Secreted proteinsFiled 2002·Application pending·0 cites
- 4453US2024317859A1Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseasesFOUNDATION FOR BIOMEDICAL RES AND INNOVATION AT KOBE·Filed 2022·Application pending·0 cites
- 4551US2024148676A1Combination therapy with pd-1 signal inhibitorUNIV KYOTO·Filed 2022·Application pending·0 cites
- 4650US6846647B1Polypeptides suppressing smooth muscle cell proliferation, the encoding cDNA, and related methodsONO PHARMACEUTICAL CO·Filed 1999·Granted Jan 25, 2005·5 cites·12 claims
- 4749US2018362650A1Pd-1 signal inhibitor combination therapyUNIV KYOTO·Filed 2016·Application pending·0 cites
- 4849US2023183347A1PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated DiseaseFOUNDATION FOR BIOMEDICAL RES AND INNOVATION AT KOBE·Filed 2021·Application pending·0 cites
- 4948US2004241745A1Substance specific to pd-1Filed 2002·Application pending·0 cites
- 5046US2022082554A1Prediction and/or Determination Marker for Effectiveness of Treatment with Drug Containing PD-1 Signal InhibitorUNIV KYOTO·Filed 2019·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tasuku Honjo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →